Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

ALNY has been the topic of several other reports. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a report on Monday, March 31st. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research report on Friday, March 21st. Chardan Capital upped their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Finally, Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a “buy” rating and a $353.00 price target for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $319.58.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $307.99 on Friday. The firm has a market cap of $40.16 billion, a price-to-earnings ratio of -141.93 and a beta of 0.22. The company’s 50 day moving average is $270.09 and its 200 day moving average is $259.10. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 52-week low of $152.30 and a 52-week high of $310.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the firm posted ($0.16) earnings per share. The firm’s revenue for the quarter was up 20.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer now directly owns 48,948 shares in the company, valued at approximately $14,978,088. This represents a 28.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Larson Financial Group LLC raised its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Whipplewood Advisors LLC grew its position in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 71 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.